HealthEquity

HealthEquity, Inc. provides range of solutions for managing health care accounts. The firm’s offers its solutions for employers, health plans, brokers, consultants and financial advisors. Its services include HAS, FSA, HRA, DCRA, 401(k), Commuter, COBRA and HIA. It also offers products like healthcare saving and spending platform, health savings accounts, investment advisory services, reimbursement arrangements, and healthcare incentives. The company was founded by Stephen D. Neeleman on September 18, 2002 and is headquartered in Draper, UT.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

HQY reports strong Q1 performance, faces challenges in seasonality and yield expectations

HQY's Q1 performance reflects strong growth and positive financial results, driven by increased HSA adoption and employer interest. However, the company faces challenges related to seasonality and yield expectations. To capitalize on opportunities, HQY should focus on reaching its enhanced rates target and addressing service fee pressures.

HealthEquity reports robust Q2 performance and eyes market expansion

HealthEquity's strong Q2 performance, driven by revenue and EBITDA growth, is supported by the enhanced rates product and expanded network partner footprint. While facing short-term challenges in interchange revenue and M&A environment changes, the company is well-positioned to capitalize on opportunities presented by market dynamics and regulatory discussions.

HealthEquity reports robust Q3 performance and optimistic fiscal '25 outlook

HealthEquity's Q3 performance showcased strong financial results, with raised fiscal '24 guidance and optimistic initial fiscal '25 guidance. The company is well-positioned to navigate challenges and capitalize on opportunities, particularly in expanding its market presence and enhancing customer satisfaction.

HealthEquity (HQY) posts record earnings, eyes growth through innovation

HealthEquity (HQY) delivered strong financial results, exceeding expectations and demonstrating growth across key metrics.
While facing challenges in certain business segments, the company's focus on technology, customer experience, and long-term quality positions it well for the future.
Opportunities for R&D acceleration, innovation through M&A, and expansion of product offerings present avenues for sustained growth and competitive advantage.

HealthEquity reports robust Q1 results, raises fiscal '24 guidance

HealthEquity's Q1 performance reflects strong financial growth and stability, with revenue, EBITDA, and HSA metrics showing positive trends.
The company's proactive approach to guidance revision, service fee optimization, and strategic partnerships positions it well for future success.
Challenges in managing fee pressures, COBRA impact, and M&A environment slowdown require focused strategies for sustained growth and market leadership.

HealthEquity reports robust Q2 results, eyes growth amid market shifts

HealthEquity's Q2 results reflect strong financial performance and strategic positioning for future growth.
Despite challenges in revenue consistency and market dynamics, the company's strengths in service quality and market leadership are key assets.
Opportunities in revenue growth, legislative changes, and market demand provide avenues for HealthEquity's continued success.

HealthEquity reports strong Q3 growth and bullish outlook for fiscal '25

HealthEquity's Q3 2024 earnings call highlighted impressive financial performance, strategic acquisitions, and optimistic guidance for fiscal '25, underlining the company's growth trajectory and market positioning.
While facing challenges in integrating acquisitions, maintaining competitive pricing, and managing asset maturation, HealthEquity remains focused on growth opportunities through enhanced yield products and consumer empowerment.
The company's emphasis on stability, profitability, and reinvestments, coupled with a proactive approach to engaging investors, sets the stage for continued success and market differentiation in the evolving healthcare landscape.

HealthEquity reports robust Q4 earnings, eyes growth through innovation

HealthEquity delivered strong financial results in Q4 2024, showcasing robust revenue growth and operational performance.
The company's focus on enhancing shareholder value, strategic mergers, and technology investments positions it well for future growth.
Challenges in pricing pressures and technology spend trends require careful navigation, while opportunities in HSA cash rates and digital innovations offer avenues for expansion.
Overall, HealthEquity's performance highlights resilience, strategic foresight, and a commitment to driving long-term value for stakeholders.

HealthEquity reports robust Q1 results, eyes cost savings and growth

HealthEquity's Q1 performance reflects strong growth in revenue, EBITDA, and HSA assets, underlining its market strength and operational efficiency.
The company's focus on cost savings, customer experience enhancement, and new sales growth positions it well for future success and market expansion.
While facing challenges in transitioning processes and managing costs, HealthEquity is leveraging opportunities in technology and market expansion to drive continued growth.

HealthEquity reports robust Q2 growth, unveils innovative healthcare payment options

HealthEquity's Q2 performance reflects strong growth and strategic initiatives to enhance healthcare payment options.
While facing challenges in margins and market conditions, the company's focus on innovation and team efforts bode well for future success.
Opportunities lie in leveraging HPAs, digital integration, and market expansion to drive continued growth and customer value.
Overall, HealthEquity's performance and outlook demonstrate resilience and a commitment to driving healthcare financial solutions.

HealthEquity reports robust Q3 growth amidst challenges and opportunities

HealthEquity's Q3 performance reflects strong growth and market positioning, despite challenges in gross profit margins.
The company's focus on legislative support, technology utilization, and diversified revenue streams positions it well for future expansion.
Opportunities in expanding the TAM, enhancing service delivery, and leveraging commuter offerings indicate a promising outlook for HealthEquity.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HealthEquity, Inc. engages in the provision of technology-enabled services for healthcare and spending decisions. The company was founded by Stephen D. Neeleman on September 18, 2002 and is headquartered in Draper, UT.

Elevance Health Inc

Investors looking for stocks in the Medical Services sector might want to consider either Elevance Health (ELV) or HealthEquity (HQY). But which of these two stocks is more attractive to value investors?

ELV vs. HQY: Which Stock Is the Better Value Option?

HealthEquity has sailed relatively smoothly since the Fed's stance on interest rates rocked the stock market. In fact, HQY stock has thrived.

HealthEquity Shields Investors From The Fed — And The IRS — With HSA Accounts

Investors looking for stocks in the Medical Services sector might want to consider either Elevance Health (ELV) or HealthEquity (HQY). But which of these two companies is the best option for those looking for undervalued stocks?

ELV vs. HQY: Which Stock Should Value Investors Buy Now?

HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock?

HealthEquity (HQY) Up 4% Since Last Earnings Report: Can It Continue?

HealthEquity (HQY) is set to receive the Conduent's HSA portfolio as a part of an agreement signed by the companies earlier this month. The deal is likely to boost HQY's business in 2024 and beyond.

HealthEquity (HQY) to Add Conduent's HSA Accounts in 2024

HealthEquity's (HQY) strength in HSA raises optimism about the stock.

3 Reasons to Hold HealthEquity (HQY) Stock in Your Portfolio

FLORHAM PARK, N.J. and DRAPER, Utah, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Conduent Incorporated (Nasdaq: CNDT), a global technology-led business solutions and services company, and HealthEquity, Inc. (Nasdaq: HQY), the nation's largest health savings account (HSA) administrator, today announced that they have entered into a definitive agreement to transfer BenefitWallet's Health Savings Account (HSA) portfolio to HealthEquity.

UPDATE: Conduent's BenefitWallet HSA Portfolio Moving to HealthEquity

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in all its segments, in the second quarter of fiscal 2024.

HealthEquity (HQY) Surpasses Q2 Earnings Estimates, FY24 View Up

HealthEquity, Inc. (NASDAQ:HQY ) Q2 2024 Earnings Conference Call September 5, 2023 4:30 PM ET Company Participants Richard Putnam - Investor Relations Jon Kessler - President & Chief Executive Officer James Lucania - Incoming Chief Financial Officer Tyson Murdock - Executive Vice President & Chief Financial Officer Steve Neeleman - Vice Chair & Founder of the Company Conference Call Participants Greg Peters - Raymond James Stan Berenshteyn - Wells Fargo Glen Santangelo - Jefferies Sean Dodge - RBC Capital Markets Scott Schoenhaus - Stephans Allen Lutz - Bank of America George Hill - Deutsche Bank Mark Marcon - Baird David Larsen - BTIG Sandy Draper - Guggenheim Operator Hello, everyone, and welcome to the conference. Please note today's conference is being recorded.

HealthEquity, Inc. (HQY) Q2 2024 Earnings Call Transcript

HealthEquity (HQY) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.47 per share. This compares to earnings of $0.33 per share a year ago.

HealthEquity (HQY) Beats Q2 Earnings and Revenue Estimates

While the top- and bottom-line numbers for HealthEquity (HQY) give a sense of how the business performed in the quarter ended July 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, HealthEquity (HQY) Q2 Earnings: A Look at Key Metrics

Delivers Record HSA Asset Growth, Margin Expansion Highlights of the second quarter include: Revenue of $243.5 million, an increase of 18% compared to $206.1 million in Q2 FY23. Net income of $10.6 million, compared to net loss of $10.7 million in Q2 FY23, with non-GAAP net income of $45.6 million, an increase of 62% compared to $28.1 million in Q2 FY23.

HealthEquity Reports Second Quarter Ended July 31, 2023 Financial Results

Here is how HealthEquity (HQY) and InMode (INMD) have performed compared to their sector so far this year.

Is HealthEquity (HQY) Outperforming Other Medical Stocks This Year?

HealthEquity is the largest player in the Health Savings Account market, with a 20% market share and the most assets under management. The company offers other consumer-directed benefits, such as flexible spending accounts and health reimbursement arrangements. HQY's revenues have been growing strongly, but its profitability has been inconsistent.

HealthEquity: A Business Model That Can't Lose?

Medpace Holdings

Surgery Partners

The Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, HQY and SGRY are set to gain the most.

3 Medical Services Stocks Countering Industry-Wide Headwinds

Here's Why You Should Invest in HealthEquity (HQY) Stock Now

Thorne HealthTech

Investors interested in Medical Services stocks are likely familiar with Thorne Healthtech, Inc. (THRN) and HealthEquity (HQY). But which of these two stocks offers value investors a better bang for their buck right now?

THRN vs. HQY: Which Stock Should Value Investors Buy Now?

Has HealthEquity (HQY) Outpaced Other Medical Stocks This Year?

Initiative will provide practical education, expert insights, and launch the 2023 HSA Guidebook Initiative will provide practical education, expert insights, and launch the 2023 HSA Guidebook

HealthEquity Announces Inaugural "HSA Week" to Increase Consumer Education and Engagement

DRAPER, Utah, Aug. 08, 2023 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation's largest health savings account (“HSA") custodian, today announced plans to release its second quarter of fiscal 2024 financial results following the close of regular stock market trading hours on Tuesday, September 5, 2023. Following the news release, HealthEquity management plans to host a conference call for investors on Tuesday, September 5, 2023, at 4:30 p.m. ET during which management will review the Company's second quarter results.

HealthEquity Sets Date to Announce Second Quarter Results Presentation at Conferences

Aptargroup

The AZEK Company

CIRCOR

SKF AB

HQY, SKFRY, AZEK, CIR and ATR have been added to the Zacks Rank #1 (Strong Buy) List on July 20, 2023.

New Strong Buy Stocks for July 20th

HealthEquity releases research findings from national employer and employee surveys HealthEquity releases research findings from national employer and employee surveys

New Data Shows Majority of HR Leaders Believe Consumer-Directed Benefits Help Employees Battle Inflation

iRadimed

With solid top and bottom-line growth on the horizon for HealthEquity (HQY) and iRadimed (IRMD), they are starting to look like viable investments for 2023 and beyond.

2 Medical Stocks to Consider Buying in June

The consensus price target hints at a 34.2% upside potential for HealthEquity (HQY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 34.21% Upside in HealthEquity (HQY): Here's What You Should Know

Investors continue to be optimistic about HealthEquity's (HQY) strength in HSA.

News for HealthEquity Stock (HQY)